Your browser doesn't support javascript.
loading
A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.
Eder, Joseph Paul; Shapiro, Geoffrey I; Appleman, Leonard J; Zhu, Andrew X; Miles, Dale; Keer, Harold; Cancilla, Belinda; Chu, Felix; Hitchcock-Bryan, Suzanne; Sherman, Laurie; McCallum, Stewart; Heath, Elisabeth I; Boerner, Scott A; LoRusso, Patricia M.
Affiliation
  • Eder JP; Early Drug Development Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Clin Cancer Res ; 16(13): 3507-16, 2010 Jul 01.
Article in En | MEDLINE | ID: mdl-20472683
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quinolines / Proto-Oncogene Proteins c-met / Vascular Endothelial Growth Factor Receptor-2 / Protein Kinase Inhibitors / Anilides / Neoplasms / Antineoplastic Agents Type of study: Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2010 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quinolines / Proto-Oncogene Proteins c-met / Vascular Endothelial Growth Factor Receptor-2 / Protein Kinase Inhibitors / Anilides / Neoplasms / Antineoplastic Agents Type of study: Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2010 Type: Article Affiliation country: United States